STOCK TITAN

IRIDEX (IRIX) SEC Filings

IRIX NASDAQ

Iridex Corporation filings document an ophthalmic medical technology issuer whose disclosures center on laser systems, delivery devices, consumables, and procedure probes for glaucoma and retinal disease applications. Form 8-K reports furnish operating and financial results, preliminary results, Regulation FD investor materials, material agreements, and other material-event disclosures.

Proxy materials describe board matters, executive compensation, equity award valuation adjustments, and pay-versus-performance information. The filing record also includes Nasdaq continued-listing compliance updates, capital-structure context such as stockholders’ equity requirements, exhibits to press releases and presentations, and Inline XBRL cover-page data for formal Exchange Act reporting.

Rhea-AI Summary

IRIDEX Corporation (IRIX) reported third-quarter revenue of $10.156 million, down 18.6% from $12.484 million a year earlier; revenue for the first nine months was $34.521 million versus $37.951 million, down 9.0%. The company attributed quarterly declines across all product groups to macroeconomic conditions and purchases pulled forward into the prior fiscal-year period. Quarterly net loss narrowed to $1.401 million from $1.573 million, and nine-month net loss narrowed to $3.191 million from $4.253 million.

Quarterly gross margin was 42.4%, compared with 32.1%, reflecting cost-reduction initiatives, including a continued shift to lower-cost contract manufacturers, partly offset by higher product costs related to tariffs. Net cash used in operating activities was $2.103 million for nine months, compared with $2.704 million. Cash and cash equivalents were $3.673 million as of October 3, 2026, versus $6.028 million as of January 3, 2026. IRIDEX reported approximately $18.5 million of purchase commitments through fiscal 2028, with $18.5 million committed for the next 12 months.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
quarterly report
-
Rhea-AI Summary

IRIDEX Corporation (IRIX) reported third-quarter 2026 revenue of $10.2 million, down 19% from $12.5 million a year earlier. Net loss was $1.4 million, compared with $1.6 million, while non-GAAP adjusted EBITDA loss was $0.6 million, versus $0.1 million. Gross margin was 42.4%, compared with 32.1%; the prior-year quarter included an approximately $0.8 million inventory write-off.

The company reduced 2026 revenue guidance to $46 million to $48 million from $51 million to $53 million; the outlook continues to exclude Middle East revenue. Adjusted operating expense guidance remains $19 million to $19.5 million, excluding depreciation and amortization and stock-based compensation. Cash and cash equivalents were $3.7 million as of October 3, 2026, down $1.0 million from July 4, 2026.

IRIDEX completed its headquarters relocation to San Jose, which it expects to deliver approximately $600,000 in annualized savings. Management cited weaker-than-expected demand in Europe and Asia, distributor probe inventory drawdowns and late-quarter order delays. It expects cash utilization to decrease significantly in the fourth quarter with stronger sales and consumption of safety stock inventory.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report
-
Rhea-AI Summary

IRIDEX Corp. reports that Novel Inspiration International Co., Ltd., a 10% owner, acquired 146,313 common shares on October 2, 2026, as a quarterly interest payment on a Convertible Promissory Note issued by IRIDEX on March 19, 2025. Novel Inspiration directly owned 697,742 shares after the transaction. Lin Shih-Yao David, also identified as a 10% owner, is Novel Inspiration’s sole officer, director and stockholder.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.69%
Tags
insider
Rhea-AI Summary

IRIDEX Corp.'s ten percent owner, Lin Shih-Yao David, reported 30 open-market purchases by Xinpo Venture Capital Co., Ltd. totaling 350,557 shares. Xinpo's March 30, 2026 purchase was 7,371 shares at $0.9900. Lin indirectly holds Xinpo shares and controls its entire ownership interest, directly and through family members. No Rule 10b5-1 plan is reported.

The reported aggregate beneficial ownership was 1,738,238 shares: 1,186,809 held through Xinpo and 551,429 through Novel Inspiration International Co., Ltd. The Novel Inspiration holdings reconcile the aggregate ownership figure and are not transactions reported here.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
29.16%
Tags
insider
-
Rhea-AI Summary

IRIDEX CORP (IRIX) is the issuer whose common stock Xinpo Venture Capital Co., Ltd. purchased in 30 reported open-market transactions totaling 266,068 shares. The purchases were indirectly attributable to Lin Shih-Yao David, a ten percent owner who controls Xinpo and has a pecuniary interest in its shares. One reported purchase was 50,000 shares at a weighted-average $0.8874 per share on June 27, 2025. No Rule 10b5-1 plan is reported for the purchases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
29.16%
Tags
insider
-
Rhea-AI Summary

IRIDEX Corp. (IRIX) 10% owner Lin Shih-Yao David reported 30 previously unreported open-market purchases of common stock by Xinpo, totaling 570,184 shares. The listed purchases span March 25, 2025, through June 5, 2025. Xinpo held the shares directly, while Lin held an indirect interest and had a pecuniary interest in them. No Rule 10b5-1 plan is reported.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
29.16%
Tags
insider
Rhea-AI Summary

IRIDEX Corp (IRIX) President and CEO Patrick Mercer reported 23,917 common shares delivered or withheld for payment of exercise price or tax liability on October 1, 2026. His reported direct common-stock holdings after the transaction were 444,867 shares; the transaction also lists a price of $0.6320 per share.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.28%
Tags
insider
-
Form 4
Rhea-AI Summary

IRIDEX CORP (IRIX) reported that Chief Financial Officer Romeo R. Dizon purchased 7,900 shares of common stock on September 16, 2026 in an open market or private transaction at $0.63 per share. Following this purchase, he directly holds 185,306 shares of IRIDEX common stock. No Rule 10b5-1 trading plan is reported.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.36%
Tags
insider
-
Rhea-AI Summary

IRIDEX CORP (IRIX) reported that its Chief Financial Officer, Romeo R. Dizon, purchased 2,354 shares of common stock on September 14, 2026 at $0.65 per share in an open-market or private transaction. Following this buy, he directly holds 177,406 shares of IRIDEX common stock. No Rule 10b5-1 trading plan is reported for this transaction.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.03%
Tags
insider
Rhea-AI Summary

IRIDEX CORP (IRIX) reported that Chief Financial Officer Romeo R. Dizon purchased 5,100 shares of common stock on September 10, 2026 at $0.68 per share in an open-market or private transaction. Following this purchase, he directly holds 175,052 shares of IRIDEX common stock. No Rule 10b5-1 trading plan is reported for this transaction.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.72%
Tags
insider

FAQ

How many IRIDEX (IRIX) SEC filings are available on StockTitan?

StockTitan tracks 98 SEC filings for IRIDEX (IRIX), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for IRIDEX (IRIX)?

The most recent SEC filing for IRIDEX (IRIX) was filed on November 17, 2026.